Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2019; 9(01): 32-34
DOI: 10.4103/AJM.AJM_171_17
CASE REPORT

Possible acute rejection associated with the use of the new antihepatitis C virus medications

Khaled Ar Karkout
Department of Internal Medicine, Tawam Hospital, AlAin, United Arab Emirates
,
Saleema Al Sherif
Department of Internal Medicine, Tawam Hospital, AlAin, United Arab Emirates
,
Qutaiba Hussein
Division of Nephrology, Tawam Hospital, AlAin, United Arab Emirates
,
Alia Albawardi
Department of Pathology, College of Medicine and Health Sciences, UAE University, AlAin, United Arab Emirates
,
Yousef Boobes
Division of Nephrology, Tawam Hospital, AlAin, United Arab Emirates
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Hepatitis C virus infection is associated with increased morbidity and mortality. It remains a major challenge for management and treatment, especially in patients with renal transplant. The new directacting antiviral agents gave big hopes to both clinicians and patients that they can overcome this challenge without major side effects. Studies recently have supported this claim; however, they are still few, limited, and may give false hopes. In the following case report, we present a case, supported by histological evidence about a possible acute rejection of kidney transplant after treatment with these new medications. This case is limited by the absence of donorspecific antibodies. This report is aimed to increase awareness about the urgent need for further studies.

Keywords

Acute rejection - anti-hepatitis C virus medication - daclatasvir - direct-acting antiviral agents - kidney transplant - sofosbuvir


Publication History

Article published online:
09 August 2021

© 2019. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 BaidAgrawal S, Pascual M, Moradpour D, Frei U, TolkoffRubin N. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol 2008; 18: 97-115
    CrossrefPubMedGoogle Scholar
  • 2 Kidney Disease: Improving Global Outcomes. Kidney Disease: Improving Global Outcomes clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73: S199
    Google Scholar
  • 3 Wéclawiack H, Kamar N, Mehrenberger M, GuilbeauFrugier C, Modesto A, Izopet J. et al. Alphainterferon therapy for chronic hepatitis C may induce acute allograft rejection in kidney transplant patients with failed allografts. Nephrol Dial Transplant 2008; 23: 1043-7
    CrossrefPubMedGoogle Scholar
  • 4 Tischer S, Fontana RJ. Drugdrug interactions with oral antiHCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol 2014; 60: 872-84
    CrossrefPubMedGoogle Scholar
  • 5 Schrezenmeier E, Galander P, Hoffmann F, Jaeger C, Lisec J, Schrezenmeier J. et al. Pharmakokinetics of daclatasvir, sofosbuvir and GS331007 in a prospective cohort of HCV positive kidney transplant recipients. Am J Transplant 2017:17 Suppl 3
  • 6 Kamar N, Marion O, Rostaing L, Cointault O, Ribes D, Lavayssière L, Sarin YK. Efficacy and safety of sofosbuvirbased antiviral therapy to treat hepatitis C virus infection after kidney transplantation. Am J Transplant 2016; 16: 14749
    CrossrefPubMedGoogle Scholar
  • 7 Xue Y, Zhang LX, Wang L, Li T, Qu YD, Liu F. et al. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. World J Gastroenterol 2017; 23: 596976
    Google Scholar
  • 8 Horn KS, Martin MT, Tang IY. Effectiveness of simeprevir and sofosbuvir in the treatment of hepatitis C virus in genotype 1 postkidney transplant recipients. American Society of Nephrology 2017
  • 9 Qu Y, Guo Y, Li T, Ye Q, Sun C, Wang L. Efficacy and safety of sofosbuvir-based interferon-free therapies for hepatitis C in liver transplant recipients. Journal of gastroenterology and hepatology 2017; 32: 740-8
    CrossrefPubMedGoogle Scholar
  • 10 Saxena V, Koraishy FM, Sise M, Lim JK, Chung RT, Liapakis A. et al. LP08: Safety and efficacy of sofosbuvircontaining regimens in hepatitis C infected patients with reduced renal function: Realworld experience from HCVtarget. J Hepatol 2015; 62: S263864
    CrossrefGoogle Scholar
  • 11 Bonacci M, Londoño MC, Esforzado N, Forns X, Sotoca JM, Campistol JM. et al. Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCVdecompensated cirrhosis: Viral eradication and removal from the liver transplant waiting list. Transpl Int 2015; 28: 13459
    CrossrefPubMedGoogle Scholar
  • 12 Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N. et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a french early access programme. Liver Int 2017; 37: 131424
    CrossrefPubMedGoogle Scholar
  • 13 Gadde S. Antineutrophil cytoplasmic antibody crescentic allograft. World J Nephrol 2016; 5: 547-50
    CrossrefPubMedGoogle Scholar